Tokyo, Sept 7, 2006 (JCN) - Takara Bio Inc., a forerunner in cancer treatment, has offered its RetroNectin for the treatment chronic lymphatic leukemia in phase-I clinical trials currently being conducted at the U.S. Memorial Sloan-Kettering Cancer Center (MSKCC).
The clinical trial targets 30 patients and will take about two to three years to complete.
This new approach of gene treatment using RetroNectin has been performed in 40 institutions around the world.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
Company Profile | Print | Alerts
 |
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial
(Jan 7, 2013)
|
|
Takara Bio Submits IND Application for HIV-1 Gene Therapy to the FDA
(Mar 23, 2012)
|
|
Takara Bio and Tianjin Medical University in Gene Therapy Project
(Aug 3, 2011)
|
|
Takara Bio RetroNectin to UCLA for TCR-gene Therapy Clinical Trials in Advanced Melanoma
(Dec 18, 2008)
|
|
Takara Bio Announces Start of Clinical Research of Cancer Immunotherapy using RetroNectin(R) Expansion Culture System at Tianjin Cancer Institute & Hospital, China
(May 2, 2008)
|
|
Takara Bio Grants Transgenomic License for LA-PCR Technology
(May 7, 2007)
|
|
ViroMed Obtains Clinical Trial Approval of Gene Therapy Treatment for Chronic Granulomatosis
(Jan 11, 2007)
|
|
Takara Bio's RetroNect Used in Australia for Gene Therapy Clinical Trials of Multiple Myeloma
(Dec 18, 2006)
|
|
Takara Bio Offers Drug for Treatment of Chronic Lymphatic Leukemia
(Sept 7, 2006)
|
|
Takara Bio Offers Drug for Treatment of Chronic Lymphatic Leukemia
(Sept 7, 2006)
|
|
|